Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Active surveillance
12 evidence topics · 12 sources
Active surveillance as the primary approach
Monitoring schedule and threshold for starting active treatment
Referral to experienced centers during active surveillance
Consensus update of June 2023: shift toward less-invasive management
“To update the 2020 global evidence-based consensus guideline on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus meeting in Milan, Italy, on June 30, 2023” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been made.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Watch and wait as the front-line approach for newly diagnosed patients
“Immediate surgery is no more the standard treatment of DF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is clear consensus that a conservative watch and wait strategy should be the front-line approach to newly diagnosed patients, irrespective of existing pain or other clinical symptoms, offering a way to understand the behavior of the disease and tailor next treatment steps.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time interval for a watch and wait approach could be 1–2 years and patients should be closely followed, preferably using contrast enhanced MRI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance in line with Desmoid Tumour Working Group and NCCN recommendations
Pooled analysis of three prospective observational studies: treatment-free survival and progression
“In this pooled analysis from three prospective observational studies on patients with extra-abdominal desmoid-type fibromatosis, we confirm that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients (n = 282) with a median follow-up of 53 months (IQR, 39–63) were included. The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 3- and 5-year PFS rates (95% CI) were 54% (48%–60%) and 51% (45%–58%), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 93 of 282 (33.0%) patients received AT after initial AS, of which 45 (48.4%) patients received AT after RECIST progression, and 48 (54.6%) patients received AT after symptomatic progression alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prospective multicenter observational study of peripheral primary sporadic tumors
“This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between 2012 and 2015, 100 patients were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%). At progression (48 patients), 23 patients received active treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italian prospective multicenter observational study at any site
“This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%]. Thirty-five of 108 (32%) patients received active treatment, 18 of 108 (17%) after RECIST progression and 17 of 108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GRAFITI prospective cohort study of non-intraabdominal tumors
“In this multicenter prospective cohort study (NTR4714), adult patients with non-intraabdominal DTF were followed during an initial AS approach for 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 105 patients started with AS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3 years, cumulative incidence of the start of active treatment was 30% (95% confidence interval [CI] 21–39) and PFS was 58% (95% CI 49–69). Median time to start active treatment and PFS were not reached at a median follow-up of 33.7 months. During AS, 32% of patients had stable disease, 28% regressed, and 40% demonstrated initial progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Larger tumor size (≥5 cm; hazard ratio = 2.38 [95% CI 1.15–4.90]) and S45F mutation (hazard ratio = 6.24 [95% CI 1.92–20.30]) were associated with the start of active treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The follow-up protocol of the GRAFITI trial consisted of follow-up visits and imaging examinations (Ultrasound [US] and MRI) at baseline, 3,6,9,12,18,24, and 36 months (window ±3 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single sarcoma reference center cohort at all anatomic locations
“Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote